• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

出现肺纤维化样改变的新冠康复患者循环中IFN-β水平较低，但IL-1α和TGF-β水平较高。

Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β.

作者信息

Colarusso Chiara, Maglio Angelantonio, Terlizzi Michela, Vitale Carolina, Molino Antonio, Pinto Aldo, Vatrella Alessandro, Sorrentino Rosalinda

机构信息

Department of Pharmacy (DIFARMA), University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.

Department of Medicine and Surgery, University of Salerno, Baronissi Campus, Via S. Allende, 84081 Baronissi, Italy.

出版信息

Biomedicines. 2021 Dec 17;9(12):1931. doi: 10.3390/biomedicines9121931.

DOI:10.3390/biomedicines9121931
PMID:34944747
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8698335/
Abstract

PURPOSE

SARS-CoV-2 infection induces in some patients a condition called long-COVID-19, herein post-COVID-19 (PC), which persists for longer than the negative oral-pharyngeal swab. One of the complications of PC is pulmonary fibrosis. The purpose of this study was to identify blood biomarkers to predict PC patients undergoing pulmonary fibrosis.

PATIENTS AND METHODS

We analyzed blood samples of healthy, anti-SARS-CoV-2 vaccinated (VAX) subjects and PC patients who were stratified according to the severity of the disease and chest computed tomography (CT) scan data.

RESULTS

The inflammatory C reactive protein (CRP), complement complex C5b-9, LDH, but not IL-6, were higher in PC patients, independent of the severity of the disease and lung fibrotic areas. Interestingly, PC patients with ground-glass opacities (as revealed by chest CT scan) were characterized by higher plasma levels of IL-1α, CXCL-10, TGF-β, but not of IFN-β, compared to healthy and VAX subjects. In particular, 19 out of 23 (82.6%) severe PC and 8 out of 29 (27.6%) moderate PC patients presented signs of lung fibrosis, associated to lower levels of IFN-β, but higher IL-1α and TGF-β.

CONCLUSIONS

We found that higher IL-1α and TGF-β and lower plasma levels of IFN-β could predict an increased relative risk (RR = 2.8) of lung fibrosis-like changes in PC patients.

摘要

目的

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染在一些患者中引发一种称为新冠后综合征（long-COVID-19，本文中称为新冠后疾病，即PC）的病症，该病症持续时间超过口咽拭子检测呈阴性的时间。PC的并发症之一是肺纤维化。本研究的目的是识别血液生物标志物，以预测发生肺纤维化的PC患者。

患者与方法

我们分析了健康、接种抗SARS-CoV-2疫苗（VAX）的受试者以及根据疾病严重程度和胸部计算机断层扫描（CT）扫描数据分层的PC患者的血液样本。

结果

PC患者中炎症性C反应蛋白（CRP）、补体复合物C5b-9、乳酸脱氢酶（LDH）升高，但白细胞介素-6（IL-6）未升高，且与疾病严重程度和肺部纤维化区域无关。有趣的是，与健康和VAX受试者相比，胸部CT扫描显示有磨玻璃影的PC患者的血浆白细胞介素-1α（IL-1α）、CXC趋化因子配体10（CXCL-10）、转化生长因子-β（TGF-β）水平较高，但干扰素-β（IFN-β）水平不高。特别是，23例严重PC患者中有19例（82.6%）和29例中度PC患者中有8例（27.6%）出现肺纤维化迹象，这与较低的IFN-β水平但较高的IL-1α和TGF-β水平相关。

结论

我们发现，较高的IL-1α和TGF-β以及较低的血浆IFN-β水平可预测PC患者发生肺纤维化样改变的相对风险增加（相对风险RR = 2.8）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/fb41d7051dd1/biomedicines-09-01931-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/6ce870106c88/biomedicines-09-01931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/05cc26f29690/biomedicines-09-01931-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/913a3cbc36f5/biomedicines-09-01931-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/8e8ab60b5526/biomedicines-09-01931-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/2c75f4cc204f/biomedicines-09-01931-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/4b9975af5b55/biomedicines-09-01931-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/fb41d7051dd1/biomedicines-09-01931-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/6ce870106c88/biomedicines-09-01931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/05cc26f29690/biomedicines-09-01931-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/913a3cbc36f5/biomedicines-09-01931-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/8e8ab60b5526/biomedicines-09-01931-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/2c75f4cc204f/biomedicines-09-01931-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/4b9975af5b55/biomedicines-09-01931-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/430c/8698335/fb41d7051dd1/biomedicines-09-01931-g007.jpg

相似文献

1
Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β.出现肺纤维化样改变的新冠康复患者循环中IFN-β水平较低，但IL-1α和TGF-β水平较高。
Biomedicines. 2021 Dec 17;9(12):1931. doi: 10.3390/biomedicines9121931.
2
Activation of the AIM2 Receptor in Circulating Cells of Post-COVID-19 Patients With Signs of Lung Fibrosis Is Associated With the Release of IL-1α, IFN-α and TGF-β.COVID-19 后肺纤维化患者循环细胞中 AIM2 受体的激活与白细胞介素 1α、干扰素-α 和转化生长因子-β 的释放有关。
Front Immunol. 2022 Jun 29;13:934264. doi: 10.3389/fimmu.2022.934264. eCollection 2022.
3
Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients.循环中较低水平的干扰素-γ是 COVID-19 患者肺纤维化的一个风险因素。
Front Immunol. 2020 Sep 29;11:585647. doi: 10.3389/fimmu.2020.585647. eCollection 2020.
4
Cytokine Patterns in COVID-19 Patients: Which Cytokines Predict Mortality and Which Protect Against?COVID-19患者的细胞因子模式：哪些细胞因子可预测死亡率，哪些可起到保护作用？
Curr Issues Mol Biol. 2022 Oct 10;44(10):4735-4747. doi: 10.3390/cimb44100323.
5
Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up.新型冠状病毒肺炎的急性后遗症：胸部CT六个月随访
Radiology. 2021 Nov;301(2):E396-E405. doi: 10.1148/radiol.2021210834. Epub 2021 Jul 27.
6
Correlation between ground-glass opacity on pulmonary CT and the levels of inflammatory cytokines in patients with moderate-to-severe COVID-19 pneumonia.肺 CT 磨玻璃密度与中重度 COVID-19 肺炎患者炎症细胞因子水平的相关性。
Int J Med Sci. 2021 Apr 16;18(11):2394-2400. doi: 10.7150/ijms.56683. eCollection 2021.
7
Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.与秘鲁 COVID-19 住院患者预后较差相关的细胞因子谱。
Front Immunol. 2021 Sep 1;12:700921. doi: 10.3389/fimmu.2021.700921. eCollection 2021.
8
Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production.慢性静脉功能不全患者的皮肤组织纤维化与转化生长因子-β1基因表达增加及蛋白生成增多有关。
J Vasc Surg. 1999 Dec;30(6):1129-45. doi: 10.1016/s0741-5214(99)70054-6.
9
The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view.细胞因子和分子通路在SARS-CoV-2感染后肺纤维化中的作用：生理病理学（再）综述
Biomedicines. 2024 Mar 13;12(3):639. doi: 10.3390/biomedicines12030639.
10
Occurrence of pulmonary residuals as one of the sequelae of COVID-19 and it's predictors among moderate and severe cases.COVID-19 后遗症之一的肺部残余物的发生及其在中重度病例中的预测因素。
Indian J Tuberc. 2021 Oct;68(4):450-456. doi: 10.1016/j.ijtb.2021.01.006. Epub 2021 Feb 3.

引用本文的文献

1
Breathless Aftermath: Post-COVID-19 Pulmonary Fibrosis.气喘吁吁的后果：新冠后肺纤维化
Viruses. 2025 Aug 9;17(8):1098. doi: 10.3390/v17081098.
2
Diabetes mellitus increases the risk of post-COVID-19 pulmonary fibrosis: a meta-analysis of observational studies.糖尿病增加新冠病毒感染后肺纤维化的风险：一项观察性研究的荟萃分析
BMC Pulm Med. 2025 Aug 12;25(1):386. doi: 10.1186/s12890-025-03880-x.
3
Long COVID and Biomarker Dysregulation-A Shift Toward Immune Exhaustion?长期新冠与生物标志物失调——是否正转向免疫耗竭？

本文引用的文献

1
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.在一个国际队列中对长期新冠进行特征描述：7个月的症状及其影响。
EClinicalMedicine. 2021 Aug;38:101019. doi: 10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15.
2
The first 12 months of COVID-19: a timeline of immunological insights.COVID-19 出现的头 12 个月：免疫学研究进展一览。
Nat Rev Immunol. 2021 Apr;21(4):245-256. doi: 10.1038/s41577-021-00522-1. Epub 2021 Mar 15.
3
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.
Medicina (Kaunas). 2025 May 28;61(6):996. doi: 10.3390/medicina61060996.
4
Long-term pulmonary sequelae and convalescent immune reactions in mild to moderate COVID-19 patients during the active treatment era.积极治疗时代轻度至中度新冠病毒肺炎患者的长期肺部后遗症及恢复期免疫反应
PLoS One. 2025 Jun 5;20(6):e0325379. doi: 10.1371/journal.pone.0325379. eCollection 2025.
5
Persistence of dysfunctional immune response 12 months after SARS-CoV-2 infection and their relationship with pulmonary sequelae and long COVID.新型冠状病毒感染12个月后功能失调的免疫反应持续存在及其与肺部后遗症和长期新冠的关系。
Respir Res. 2025 Apr 17;26(1):152. doi: 10.1186/s12931-025-03200-1.
6
A blood-based mRNA signature distinguishes people with Long COVID from recovered individuals.一种基于血液的mRNA特征可将长期新冠患者与康复者区分开来。
Front Immunol. 2024 Dec 3;15:1450853. doi: 10.3389/fimmu.2024.1450853. eCollection 2024.
7
Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era.新型冠状病毒2型相关心肌纤维化的可能机制：大流行后时代的思考
Front Microbiol. 2024 Oct 8;15:1470953. doi: 10.3389/fmicb.2024.1470953. eCollection 2024.
8
The Diagnostic and Predictive Value of Biomarkers for Pulmonary Fibrosis in Patients with Coronavirus Disease 2019.2019冠状病毒病患者肺纤维化生物标志物的诊断和预测价值
J Glob Infect Dis. 2024 May 24;16(2):45-53. doi: 10.4103/jgid.jgid_150_23. eCollection 2024 Apr-Jun.
9
Prospects for the Protective Mechanisms and Compounds of Bufei Huoxue Capsule against COVID-19 Convalescence: Evaluation of Integrating UHPLC-HRMS Analysis and Network Pharmacology Strategy.补肺活血胶囊对新型冠状病毒肺炎恢复期的保护机制及化合物研究前景：基于超高效液相色谱-高分辨质谱分析与网络药理学策略的评估
Comb Chem High Throughput Screen. 2024 Jun 12. doi: 10.2174/0113862073296539240527064736.
10
Pathophysiological, immunological, and inflammatory features of long COVID.长新冠的病理生理、免疫和炎症特征。
Front Immunol. 2024 Feb 28;15:1341600. doi: 10.3389/fimmu.2024.1341600. eCollection 2024.
白细胞介素 1α：白细胞介素 1α 在自身免疫性和炎症性疾病发病机制和治疗中的作用的综合综述。
Autoimmun Rev. 2021 Mar;20(3):102763. doi: 10.1016/j.autrev.2021.102763. Epub 2021 Jan 20.
4
C-reactive protein and clinical outcomes in patients with COVID-19.C 反应蛋白与 COVID-19 患者的临床结局。
Eur Heart J. 2021 Jun 14;42(23):2270-2279. doi: 10.1093/eurheartj/ehaa1103.
5
COVID-19 vaccines: The status and perspectives in delivery points of view.COVID-19 疫苗：交付观点中的现状和展望。
Adv Drug Deliv Rev. 2021 Mar;170:1-25. doi: 10.1016/j.addr.2020.12.011. Epub 2020 Dec 24.
6
How and why patients made Long Covid.患者如何以及为何出现长新冠。
Soc Sci Med. 2021 Jan;268:113426. doi: 10.1016/j.socscimed.2020.113426. Epub 2020 Oct 7.
7
T cell immunity to SARS-CoV-2 following natural infection and vaccination.自然感染和接种疫苗后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的T细胞免疫
Biochem Biophys Res Commun. 2021 Jan 29;538:211-217. doi: 10.1016/j.bbrc.2020.10.060. Epub 2020 Oct 23.
8
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
9
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.COVID-19 危重症患者的 I 型 IFN 免疫先天缺陷。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
10
Post-COVID-19 pneumonia pulmonary fibrosis.新型冠状病毒肺炎后肺纤维化
QJM. 2020 Nov 1;113(11):837-838. doi: 10.1093/qjmed/hcaa255.